Unexpected Adverse Events of Immune Checkpoint Inhibitors
暂无分享,去创建一个
[1] A. Meirovitz,et al. Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience , 2023, International journal of molecular sciences.
[2] O. A. Abu Saleh,et al. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors , 2022, Cancers.
[3] J. Koivunen,et al. Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study , 2022, Cancers.
[4] A. Yakobson,et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review , 2021, Cancers.
[5] E. Calvo,et al. Clinical Challenges of Immune Checkpoint Inhibitors. , 2020, Cancer cell.
[6] M. Milone,et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy , 2020, Brain communications.
[7] M. Lacouture,et al. CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. , 2020, Journal of the American Academy of Dermatology.
[8] N. Peled,et al. Associated Myocarditis: A Predictive Factor for Response? , 2020, Case Reports in Oncology.
[9] J. Larkin,et al. How we treat neurological toxicity from immune checkpoint inhibitors , 2019, ESMO Open.
[10] A. Mammen,et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study , 2019, Journal of Immunotherapy for Cancer.
[11] N. M. La‐Beck,et al. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines , 2019, Asia-Pacific journal of oncology nursing.
[12] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[13] Laura C. Cappelli,et al. Rheumatic immune-related adverse events from cancer immunotherapy , 2018, Nature Reviews Rheumatology.
[14] A. Sreih,et al. Vasculitis associated with immune checkpoint inhibitors—a systematic review , 2018, Clinical Rheumatology.
[15] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[16] Ami A. Shah,et al. Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature , 2017, Arthritis care & research.
[17] Linghong Guo,et al. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials , 2017, Drug design, development and therapy.
[18] A. Khachemoune,et al. Paraneoplastic palmoplantar keratoderma secondary to metastatic uterine adenocarcinoma. , 2017, Cutis.
[19] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[20] J. Callen,et al. Cutaneous Manifestations of Internal Malignancy , 2009, CA: a cancer journal for clinicians.
[21] I. B. Wu,et al. Reiter's syndrome: the classic triad and more. , 2008, Journal of the American Academy of Dermatology.
[22] B. Robinson,et al. IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 1 , 2003, The Journal of Immunology.